MaxLinear, Inc. (MXL) Reaches $17.67 52-Week Low; Dafna Capital Management Boosted Akebia Therapeutics (AKBA) Stake

June 17, 2018 - By Michael Collier

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Logo

The stock of MaxLinear, Inc. (NYSE:MXL) hit a new 52-week low and has $17.14 target or 3.00% below today’s $17.67 share price. The 6 months bearish chart indicates high risk for the $1.20 billion company. The 1-year low was reported on Jun, 17 by Barchart.com. If the $17.14 price target is reached, the company will be worth $36.12 million less. The stock decreased 0.73% or $0.13 during the last trading session, reaching $17.67. About 1.49 million shares traded or 111.65% up from the average. MaxLinear, Inc. (NYSE:MXL) has declined 39.49% since June 17, 2017 and is downtrending. It has underperformed by 52.06% the S&P500. Some Historical MXL News: ; 02/04/2018 – MaxLinear, Inc. Announces the Departure of its CFO and Reaffirms Financial Guidance for 1Q 2018; 14/03/2018 – MaxLinear’s MxL7704 Power Management IC Powers the Raspberry Pi 3 Model B+; 02/05/2018 – MaxLinear and devolo Team for New G.hn Wireless, IPTV Products for Carriers; 02/04/2018 – MAXLINEAR: ADAM SPICE, CFO, TO LEAVE ON MAY 23; 21/04/2018 – DJ MaxLinear inc, Inst Holders, 1Q 2018 (MXL); 12/03/2018 – MaxLinear to Showcase Industry’s First 400G Data Center Transceiver Chipset at OFC 2018; 02/04/2018 – MAXLINEAR, REPORTS DEPARTURE OF CFO & REAFFIRMS FINL GUIDANCE F; 02/04/2018 – MAXLINEAR INC – ADAM SPICE, CFO, TO LEAVE MAXLINEAR ON MAY 23; 08/05/2018 – MAXLINEAR SEES 2Q REV. $100M TO $110.0M, EST. $118.0M; 02/04/2018 – MAXLINEAR INC – REAFFIRMS FINANCIAL GUIDANCE FOR 1Q 2018

Dafna Capital Management Llc increased Akebia Therapeutics Inc (AKBA) stake by 349.94% reported in 2018Q1 SEC filing. Dafna Capital Management Llc acquired 475,000 shares as Akebia Therapeutics Inc (AKBA)’s stock declined 31.79%. The Dafna Capital Management Llc holds 610,738 shares with $5.82 million value, up from 135,738 last quarter. Akebia Therapeutics Inc now has $621.17 million valuation. The stock decreased 1.97% or $0.22 during the last trading session, reaching $10.92. About 573,001 shares traded or 17.83% up from the average. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has declined 25.63% since June 17, 2017 and is downtrending. It has underperformed by 38.20% the S&P500. Some Historical AKBA News: ; 23/04/2018 – DJ Akebia Therapeutics Inc, Inst Holders, 1Q 2018 (AKBA); 30/05/2018 – Akebia Therapeutics Closes Below 50-Day Average: Technicals; 22/03/2018 – Akebia Therapeutics Announces Proposed Public Offering of Common Stk; 21/05/2018 – Akebia Therapeutics Presenting at UBS Conference Tomorrow; 15/05/2018 – Ecor1 Capital Buys New 2.5% Position in Akebia Therapeutics; 12/03/2018 Akebia Therapeutics 4Q Rev $87.3M; 09/05/2018 – AKEBIA THERAPEUTICS – EXISTING CASH RESOURCES & COMMITTED CAPITAL FROM COLLABORATION PARTNERS EXPECTED TO FUND CURRENT OPERATING PLAN INTO EARLY 2020; 03/04/2018 – Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4); 22/03/2018 – AKEBIA – INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED CLINICAL DEVELOPMENT, OPTIMIZATION OF VADADUSTAT PROGRAM; 12/03/2018 – Akebia Therapeutics 4Q EPS 25c

Since January 9, 2018, it had 0 insider buys, and 5 insider sales for $2.41 million activity. LaChance Michael J. also sold $576,925 worth of MaxLinear, Inc. (NYSE:MXL) shares. Kwong Connie H. sold $28,957 worth of stock. 25,018 shares valued at $700,554 were sold by WALSH BRENDAN on Tuesday, January 9. The insider LING CURTIS sold 22,321 shares worth $511,084.

Among 12 analysts covering Maxlinear Inc. (NYSE:MXL), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Maxlinear Inc. had 41 analyst reports since September 17, 2015 according to SRatingsIntel. Needham maintained it with “Buy” rating and $18 target in Wednesday, November 4 report. Stifel Nicolaus maintained MaxLinear, Inc. (NYSE:MXL) rating on Wednesday, September 27. Stifel Nicolaus has “Buy” rating and $33.0 target. The firm has “Buy” rating by Needham given on Wednesday, January 25. The stock of MaxLinear, Inc. (NYSE:MXL) has “Buy” rating given on Wednesday, August 9 by Deutsche Bank. The stock has “Buy” rating by Roth Capital on Tuesday, February 13. The firm has “Buy” rating by Roth Capital given on Wednesday, September 30. The firm earned “Buy” rating on Wednesday, May 9 by Stifel Nicolaus. The stock of MaxLinear, Inc. (NYSE:MXL) earned “Buy” rating by Deutsche Bank on Tuesday, August 9. The firm has “Buy” rating by Needham given on Wednesday, August 9. The company was maintained on Wednesday, January 13 by Roth Capital.

More news for MaxLinear, Inc. (NYSE:MXL) were recently published by: Businesswire.com, which released: “TOT Launches New Gigabit Broadband Access Service Powered by MaxLinear’s G.hn Technology” on June 14, 2018. Businesswire.com‘s article titled: “MaxLinear and Hitron Partner On Multi-Gigabit MoCA 2.5 Broadband Access Client Devices” and published on June 13, 2018 is yet another important article.

Analysts await MaxLinear, Inc. (NYSE:MXL) to report earnings on August, 14. They expect $0.23 EPS, down 14.81% or $0.04 from last year’s $0.27 per share. MXL’s profit will be $15.67M for 19.21 P/E if the $0.23 EPS becomes a reality. After $0.27 actual EPS reported by MaxLinear, Inc. for the previous quarter, Wall Street now forecasts -14.81% negative EPS growth.

MaxLinear, Inc. provides radio-frequency and mixed-signal circuits for broadband communications, data center, metro, and long-haul transport network applications worldwide. The company has market cap of $1.20 billion. The firm offers RF receivers and RF receiver systems-on-chips to receive and demodulate broadband signals, modem solutions, and physical medium devices that provide a constant current source, current-to-voltage regulation, and data alignment and retiming functionality in optical interconnect applications. It currently has negative earnings. The Company’s products are integrated into a range of electronic devices, including cable and terrestrial and satellite set-top boxes and gates, DOCSIS data and voice gateways, hybrid analog and digital televisions, satellite low-noise blocker transponders or outdoor units, and physical medium devices, as well as RF transceiver and modem devices for wireless access and backhaul applications.

Investors sentiment is 1.06 in 2018 Q1. Its the same as in 2017Q4. It has no change, as 18 investors sold MaxLinear, Inc. shares while 52 reduced holdings. only 18 funds opened positions while 56 raised stakes. 57.04 million shares or 5.89% more from 53.87 million shares in 2017Q4 were reported. Gemmer Asset Mgmt Ltd Llc reported 0% of its portfolio in MaxLinear, Inc. (NYSE:MXL). Aperio Group Ltd Company invested 0% of its portfolio in MaxLinear, Inc. (NYSE:MXL). 898,648 were reported by Wells Fargo And Mn. Morgan Stanley holds 168,054 shares. Vanguard Group Incorporated Inc has 5.84 million shares for 0.01% of their portfolio. Alliancebernstein Lp holds 0% or 100,232 shares. Moreover, Grandeur Peak Glob Limited Com has 0.02% invested in MaxLinear, Inc. (NYSE:MXL). Tower Cap Ltd Liability Corp (Trc) reported 1,673 shares or 0% of all its holdings. Kennedy stated it has 115,883 shares or 0.05% of all its holdings. Ranger Investment Mngmt Limited Partnership stated it has 1.21% of its portfolio in MaxLinear, Inc. (NYSE:MXL). Wellington Management Group Incorporated Llp holds 0% or 764,365 shares. Rice Hall James & Associates Ltd Liability Company has 518,491 shares for 0.46% of their portfolio. Envestnet Asset, Illinois-based fund reported 7,599 shares. National Bank & Trust Of New York Mellon Corp invested 0.01% in MaxLinear, Inc. (NYSE:MXL). State Of Wisconsin Inv Board reported 608,200 shares stake.

Investors sentiment increased to 1.9 in 2018 Q1. Its up 0.27, from 1.63 in 2017Q4. It increased, as 14 investors sold AKBA shares while 28 reduced holdings. 37 funds opened positions while 43 raised stakes. 39.14 million shares or 29.30% more from 30.27 million shares in 2017Q4 were reported. Bluemountain Capital Mgmt Limited Co reported 58,167 shares. Los Angeles Management And Equity Rech stated it has 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). 8,259 were accumulated by Legal & General Grp Public Limited Company. First Manhattan Com holds 0.03% or 565,066 shares. Panagora Asset Mgmt reported 0% stake. Nantahala Mgmt Ltd Liability accumulated 3.39M shares. Federated Invsts Pa has invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). American Gp stated it has 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). 2.36 million were reported by Vanguard Grp Inc. The Alberta – Canada-based Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Management has invested 0.01% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Balyasny Asset Management Limited Liability Corp reported 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Foundry Prns holds 54,741 shares. New York State Common Retirement Fund owns 52,670 shares. Citadel Advsr Limited Liability Corp, a Illinois-based fund reported 229,314 shares. Virtu Financial reported 23,352 shares.

Among 11 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Akebia Therapeutics Inc had 25 analyst reports since August 13, 2015 according to SRatingsIntel. On Wednesday, December 21 the stock rating was maintained by JMP Securities with “Mkt Outperform”. Mizuho initiated it with “Buy” rating and $24.0 target in Wednesday, October 4 report. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) has “Buy” rating given on Thursday, December 7 by BTIG Research. The firm has “Overweight” rating given on Wednesday, September 9 by Morgan Stanley. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) has “Buy” rating given on Tuesday, June 6 by H.C. Wainwright. Mizuho maintained the stock with “Buy” rating in Wednesday, March 7 report. The firm has “Equal Weight” rating given on Thursday, August 13 by Morgan Stanley. On Thursday, August 13 the stock rating was maintained by Brean Capital with “Buy”. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock has “Buy” rating by H.C. Wainwright on Monday, July 10.

Dafna Capital Management Llc decreased Beigene Ltd stake by 54,019 shares to 7,330 valued at $1.23 million in 2018Q1. It also reduced Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) stake by 218,576 shares and now owns 974,652 shares. Zogenix Inc was reduced too.

MaxLinear, Inc. (NYSE:MXL) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>